<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675008</url>
  </required_header>
  <id_info>
    <org_study_id>SMC 2020-09-117</org_study_id>
    <nct_id>NCT04675008</nct_id>
  </id_info>
  <brief_title>Central Nervous System(CNS) Efficacy of Dacomitinib</brief_title>
  <official_title>A Phase II Study of Dacomitinib in Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer (NSCLC) Patients Who Have Non-irradiated Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, phase II study of dacomitinib in advanced EGFR-mutant NSCLC patients&#xD;
      who have non-irradiated brain metastasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CNS objective response rate (Complete response or Partial response)</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of CR or PR of CNS disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CNS progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from enrollment to CNS progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of CNS failure by competing risk analysis</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the CNS efficacy of dacomitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial objective response rate</measure>
    <time_frame>1 year</time_frame>
    <description>The rate of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from enrollment to progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Time from enrollment to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>1 year</time_frame>
    <description>The % of side effect</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Study arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dacomitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacomitinib</intervention_name>
    <description>Secondary generation EGFR-tyrosine kinase inhibitor (TKI) (Dacomitinib) for EGFR mutant NSCLC patients with non irradiated brain metastasis</description>
    <arm_group_label>Study arm</arm_group_label>
    <other_name>Vizimpro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven recurrent or metastatic NSCLC (adenocarcinoma) with major EGFR mutation&#xD;
             (exon 19 deletion or Leu858Arg mutation without the Thr790Met)&#xD;
&#xD;
          -  No prior systemic treatment of advanced NSCLC (Neoadjuvant or adjuvant chemotherapy&#xD;
             are allowed, without limitation on its treatment timing)&#xD;
&#xD;
          -  Age ≥20 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Had at least one measurable intracranial lesion as ≥ 5mm in the longest diameter by&#xD;
             magnetic resonance imaging (MRI) (≥ 5mm by thin section (1.2mm) of brain MRI image, ≥&#xD;
             10mm by less thin section(2.5mm) brain MRI ), which checked within 4 weeks before&#xD;
             enrollment. If MRI slice thickness is not appropriate, we need to recheck Brain MRI&#xD;
&#xD;
          -  Number of brain metastasis =&gt;5&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Female subjects must either be of non-reproductive potential&#xD;
&#xD;
          -  Subject is willing and able to comply with the protocol&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe symptomatic brain metastasis, needing urgent control with radiotherapy or high&#xD;
             dose steroid: the definition of high dose steroid is the equivalent dose of&#xD;
             dexamethasone 10 mg or higher per day (mild symptoms controlled with low dose of&#xD;
             steroid can be enrolled)&#xD;
&#xD;
          -  With leptomeningeal seeding&#xD;
&#xD;
          -  Exposure to EGFR-TKIs or other EGFR targeting agents at any time in either neoadjuvant&#xD;
             or adjuvant setting&#xD;
&#xD;
          -  Local treatment (stereotatic radiosurgery or whole brain radiotherapy) for brain&#xD;
             metastases&#xD;
&#xD;
          -  Uncontrolled systemic illness including uncontrolled hypertension, active bleeding, or&#xD;
             active infection.&#xD;
&#xD;
          -  Past medical history of interstitial lung disease, drug induced interstitial lung&#xD;
             disease, radiation pneumonitis which required steroid treatment&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jong-Mu Sun, MD</last_name>
    <phone>822-3410-1795</phone>
    <email>jongmu.sun@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jong-Mu Sun</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Mu Sun</last_name>
      <phone>82234103459</phone>
      <phone_ext>82234103459</phone_ext>
      <email>jongmu.sun@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>January 1, 2021</last_update_submitted>
  <last_update_submitted_qc>January 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Jong-Mu Sun</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

